GetTopicDetailResponse(id=c17293944e0, topicName=達(dá)格列嗪, introduction=達(dá)格列嗪, content=null, image=null, comments=3, allHits=1085, url=https://h5.medsci.cn/topic?id=93944, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=90846, tagList=[TagDto(tagId=90846, tagName=達(dá)格列嗪)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1954907, encodeId=97f7195490ec3, content=<a href='/topic/show?id=c17293944e0' target=_blank style='color:#2F92EE;'>#達(dá)格列嗪#</a>, objectTitle=阿斯利康的SGLT2抑制劑達(dá)格列嗪治療心力衰竭獲得FDA的快速通道認(rèn)證, objectType=article, longId=179624, objectId=489d1e96248e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=489d1e96248e, replyNumber=0, likeNumber=78, createdTime=2020-02-05, rootId=0, userName=仁醫(yī)06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=489d1e96248e, moduleTitle=阿斯利康的SGLT2抑制劑達(dá)格列嗪治療心力衰竭獲得FDA的快速通道認(rèn)證, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=489d1e96248e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954905, encodeId=744d19549052f, content=<a href='/topic/show?id=c17293944e0' target=_blank style='color:#2F92EE;'>#達(dá)格列嗪#</a>, objectTitle=2019 ADA：阿斯利康的SGLT2抑制劑達(dá)格列嗪可減輕2型糖尿病腎病, objectType=article, longId=168050, objectId=2d6716805018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6716805018, replyNumber=0, likeNumber=165, createdTime=2020-02-22, rootId=0, userName=仁醫(yī)06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6716805018, moduleTitle=2019 ADA：阿斯利康的SGLT2抑制劑達(dá)格列嗪可減輕2型糖尿病腎病, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2d6716805018)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954906, encodeId=0099195490666, content=<a href='/topic/show?id=c17293944e0' target=_blank style='color:#2F92EE;'>#達(dá)格列嗪#</a>, objectTitle=FDA授予AstraZeneca糖尿病藥物達(dá)格列嗪治療慢性腎病的快速指定, objectType=article, longId=178300, objectId=a66d1e83002b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a66d1e83002b, replyNumber=0, likeNumber=0, createdTime=2020-01-04, rootId=0, userName=仁醫(yī)06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a66d1e83002b, moduleTitle=FDA授予AstraZeneca糖尿病藥物達(dá)格列嗪治療慢性腎病的快速指定, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a66d1e83002b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
